Peptide-Coated Nanoparticles Enable Oral Delivery of Exenatide by Crossing the Gut and Reaching the Liver
Nanoparticles decorated with a small cyclic FcRn-binding peptide crossed the intestinal barrier, avoided protein corona formation, and successfully delivered the peptide drug exenatide orally in diabetic mice — producing significant blood sugar reduction.
Quick Facts
What This Study Found
Small cyclic FcRn-binding peptide-decorated nanoparticles showed superior intestinal transport, reduced protein corona formation, and effective oral delivery of exenatide in diabetic mice compared to larger IgG-decorated nanoparticles.
Key Numbers
Mesoporous silica nanoparticles (MSNs) with ligand modifications; demonstrated GI survival and liver targeting with reduced protein corona.
How They Did This
Functionalized mesoporous silica nanoparticles with either a small cyclic FcRn-binding peptide (MSNs-FcBP) or large IgG Fc fragments (MSNs-Fc). Compared mucus diffusion, intestinal transport, protein corona formation, and liver accumulation. Conducted pharmacokinetic and pharmacodynamic studies in diabetic mice with oral exenatide delivery.
Why This Research Matters
Oral delivery of peptide drugs would eliminate the need for daily injections — a major barrier to patient compliance for diabetes and other chronic diseases. This study demonstrates that the right surface coating (a small peptide vs. a large protein) can make or break oral nanoparticle delivery by controlling protein corona formation.
The Bigger Picture
This work addresses one of pharmaceutical science's biggest challenges: making peptide drugs orally available. The key insight — that smaller targeting ligands outperform larger ones by reducing protein corona formation — is broadly applicable beyond exenatide. It could transform delivery of GLP-1 agonists, insulin, and other peptide therapeutics that currently require injection.
What This Study Doesn't Tell Us
Mouse study — human GI tract physiology differs significantly. Long-term safety of silica nanoparticle accumulation in the liver needs assessment. The exenatide dose delivered orally may not match injectable bioavailability. Scale-up of peptide-functionalized nanoparticles for manufacturing is complex.
Questions This Raises
- ?What percentage of the oral exenatide dose actually reaches systemic circulation compared to injection?
- ?Is the silica nanoparticle carrier safe for repeated daily dosing over months to years?
- ?Can this FcRn-binding peptide approach work for larger peptide drugs like insulin or semaglutide?
Trust & Context
- Key Stat:
- Significant hypoglycemic response oral exenatide delivered via FcRn-binding peptide nanoparticles in diabetic mice — with superior gut transport and reduced protein corona vs. antibody-coated particles
- Evidence Grade:
- Preliminary — animal study demonstrating proof-of-concept for oral peptide delivery in a diabetic mouse model. Compelling pharmacokinetic and pharmacodynamic data, but human translation is unproven.
- Study Age:
- Published in 2024, addressing the cutting-edge challenge of oral peptide drug delivery using nanoparticle technology.
- Original Title:
- Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.
- Published In:
- ACS nano, 18(52), 35310-35324 (2024)
- Authors:
- Wang, Jie, Zhang, Zilong, Zhang, Zhuan, Zou, Zhiwen, Zhuo, Yan, Liu, Chang, Nie, Di, Gan, Yong, Yu, Miaorong
- Database ID:
- RPEP-09475
Evidence Hierarchy
Frequently Asked Questions
Why can't you just swallow a pill of exenatide?
Peptide drugs like exenatide are made of amino acids — the same building blocks your body digests as food. When you swallow a peptide, stomach acid and digestive enzymes break it apart before it can be absorbed. These nanoparticles protect exenatide from digestion and use a clever surface coating (a peptide that binds a receptor on gut cells) to ferry the drug across the intestinal wall and into the bloodstream.
Why does the size of the surface coating matter so much?
When nanoparticles enter the body, blood proteins immediately coat their surface (forming a 'protein corona'). This coating acts like a flag that tells immune cells to destroy the particles. Smaller surface coatings attract fewer proteins, so the nanoparticles avoid immune detection better and deliver more drug to the target. It's like wearing camouflage — a sleeker design blends in better.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09475APA
Wang, Jie; Zhang, Zilong; Zhang, Zhuan; Zou, Zhiwen; Zhuo, Yan; Liu, Chang; Nie, Di; Gan, Yong; Yu, Miaorong. (2024). Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.. ACS nano, 18(52), 35310-35324. https://doi.org/10.1021/acsnano.4c11453
MLA
Wang, Jie, et al. "Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.." ACS nano, 2024. https://doi.org/10.1021/acsnano.4c11453
RethinkPeptides
RethinkPeptides Research Database. "Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified..." RPEP-09475. Retrieved from https://rethinkpeptides.com/research/wang-2024-enhanced-guttoliver-oral-drug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.